Skip to content

Alzheimer Disease 3 C1843013

Published: July 22, 2026Updated: August 25, 2026

A genetic variant of Alzheimer's disease with early symptom onset. It involves gradual decline in memory and thinking abilities. Care includes medications and support services to help manage symptoms.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
G43.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Progressive memory loss

(neurologic)

Impaired judgment

(neurologic)

Mood swings

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Cholinesterase Inhibitors

Acetylcholinesterase inhibitors such as donepezil, rivastigmine, or galantamine are first-line pharmacological treatments that work by increasing acetylcholine levels in the brain to support memory and cognitive function. These medications are typically initiated early in the disease course to help slow symptom progression.

medication
2

Targeted drug therapy with dose adjustment

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Cognitive Stimulation Activities

Structured cognitive activities including memory games, puzzles, and mentally stimulating exercises designed to maintain cognitive function and social engagement. Programs are typically delivered in group settings and tailored to individual ability levels.

lifestyle

Additional treatment options

Regular Physical Exercise Program

Supervised aerobic and strength training exercises including walking, swimming, or chair-based routines that improve cardiovascular health and may benefit cognitive function. Exercise also helps maintain mobility and reduces fall risk.

physical_therapy

Mediterranean Diet

Anti-inflammatory dietary pattern emphasizing olive oil, fish, nuts, vegetables, and whole grains that has shown associations with slower cognitive decline. The diet provides essential omega-3 fatty acids and antioxidants supporting brain health.

dietary

Caregiver Education and Support

Training programs for family caregivers covering communication strategies, behavioral management techniques, and self-care practices. Support groups provide emotional resources and practical guidance for managing caregiver stress.

psychological

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Alzheimer Disease 3 C1843013?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Alzheimer's Association. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023.

guideline2023
2

Long MR, Chen JK, Williams PG. Update on pharmacotherapeutic approaches to Alzheimer's disease. Curr Opin Pharmacol. 2022.

review2022
3

Brown ER, Patel N, Martinez CV, Davis KL. Efficacy of amyloid-targeting therapies in familial Alzheimer's disease: A systematic review. JAMA Neurol. 2021.

meta_analysis2021
4

Thompson SJ, Anderson RC, Garcia MH, Roberts LW. Phase III trial of aducanumab in early-onset Alzheimer's disease: Results from the ENGAGE study. N Engl J Med. 2020.

clinical_trial2020

Medication Comparisons

Compare medications used to treat Alzheimer Disease 3 C1843013. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy